The patient, a 58-year-old white male, was diagnosed with a nonhypercellular, nontumoral B-cell ALL in May 2002. Blast cells were CD 10 þ , CD19 þ , CD22 þ , CD 79a þ . CD52 was not tested (not present in the routine panel). Chromosome analysis showed a clonal population with the inversion i (7)(q10) in 3/21 mitoses. There was no specific marker by molecular biology, and the bcr-abl transcript was not detected.
The patient was treated according to the French LALA 94 national protocol. 6 Blast disappearance was achieved after a first course combining steroids, daunorubicin vincristine and cyclophosphamide, with however no full normal haemopoiesis recovery. The course was complicated by severe encephalitis attributed to drug toxicity. Three subsequent consolidation courses (rotating agents) were given. The patient had no family donor for an allogeneic stem cell transplantation and failed attempts at mobilizing peripheral blood stem cells in view of an autograft.
On December 2002, he became deeply pancytopenic and a bone marrow aspiration showed an early relapse with 3% blast cells bearing the same immunophenotypical and chromosome abnormalities seen at initial diagnosis. The patient was in poor clinical condition. In view of the previous encephalitis following the first induction course and the absence of full haemopoietic recovery since initial diagnosis, it was decided an attempt with alemtuzumab rather than conventional chemotherapy. From 19 December 2002, the patient received alemtuzumab alone at a dose of 30 mg, 3 days per week for 4 weeks. Blast cells disappeared from the marrow by cytology, immunophenotyping and chromosome analysis. He however remained cytopenic with haemoglobin 9g/dl; leucocytes 700/mm 3 ; platelets 33000/ mm 3 . Erythropoietin and granulocyte-colony stimulating factor (G-CSF) were given.
Alemtuzumab was pursued at a dose of 30 mg 3 days a week, every 2 months. Prophylaxis of infection consisted in valacyclovir, atovaquone, itraconazole and fluconazole p.o. Although the patient had a past history of pulmonary and urogenital tuberculosis, no specific prevention was carried out. There was no infectious complication and the patient resumed normal professional activity. After the third course, alemtuzumab administration was constantly followed by generalized erythroderma peaking on day 15 following first infusion and fading away spontaneously (no steroids) at time of next course. A marrow aspiration in September 2003 was normal. On 1 May 2004, 16 months after beginning alemtuzumab treatment, the patient is disease free but cytopenic (haemoglobin 12.5 g/dl; neutrophils 1900/mm 3 ; platelets 95000/mm 3 ) with a profound lymphopenia (145/mm 3 ). Alemtuzumab is here reported as having controlled B-ALL blast cells for more than a year in an adult patient who relapsed on therapy within 6 months. This observation may be of importance in indicating a potential role for alemtuzumab in the treatment of adult ALL. We however cannot rule out an additional effect of the cytokines administered in association for maintenance, since the main tumor killing mechanism with alemtuzumab in vivo involves FcR gamma III receptors on the surface of polymorphonuclear leucocytes, which mediate antibody-dependant cellular cytotoxicity. 3 Either alemtuzumab alone or alemtuzumab and G-CSF should be tested further. The TEL gene (also known as ETV6), encoding a protein of the ETS transcription factor family, is involved in various rearrangements of human malignancies. 1 The partner genes identified to date can be classified into two main subtypes according to the function of their encoded product: gene encoding proteins with tyrosine kinase activity and gene encoding transcription factors. The situation is less clear in several uncommon chromosome translocations involving TEL, which do not result in obvious fusion product. 2 They might sometimes result in the transcriptional activation of genes located in the vicinity of the breakpoint on the translocated chromosome partner, or in the partial inactivation of TEL. 3 In most of the fusion proteins including TEL, the TEL moiety provides a strong oligomerization domain (SAM domain) or transcriptional repression properties.
The MN1-TEL fusion does not fit into this schema. The MN1 gene was at first identified from analysis of t(4;22)(p16;q11) in meningioma cells. MN1 encodes a transcription co-factor weakly expressed in various normal tissues. 4, 5 The MN1-TEL fusion resulting from t(12;22)(p13;q11) is an uncommon example of fusion involving TEL, which occurs in acute leukemias and myelodysplastic syndromes and is expressed from the MN1 promoter. Two types of MN1-TEL fusion have been reported, MN1-TEL type I in which the SAM domain is conserved and type II in which the SAM domain is disrupted. The oligomerization properties of TEL are disrupted in both types of MN1-TEL fusion protein and they both possess strong transcriptional activation and transformation properties. We characterized the expression of TEL, MN1, and MN1-TEL in the human leukemic cell line UCSD/AML1 with t(12;22)(p13;q11), which is a suitable tool for the study of the MN1-TEL biological properties.
We analyzed two cell lines with a t(12;22)(p13;q11): the UCSD/AML1 cell line, kindly provided by Dr HG Drexler (German Collection of Microorganisms and Cell cultures, Braunschweig) established by Oval et al from a patient with mixed acute leukemia in relapse. 6 The karyotype was 45,XX,t(3;3)(q21;q26),À7,t(12;22)(p13;q11), as previously described. The MUTZ-3 cell line established from the cells of a patient with acute myelomonocytic leukemia, provided by Dr HG Drexler, has a complex karyotype including t(12;22)(p13;q11). 7 FISH experiments were carried out using the following probes: for chromosome 12, YAC 936E2 covering TEL and cosmids encompassing the TEL locus 179A6, 50F4, 2G8, 184C4, 54D5, 148B6 (a kind gift of P Marynen, Leuven), and for chromosome 22, PAC dJ213J1 and BAC CTA-437G10 covering the MN1 locus. The YAC 936E, encompassing the TEL locus, hybridized to the normal 12, and to derivative chromosomes 12 and 22 in the two cell lines with t(12;22). In the UCSD/AML1 cell line, cosmids 179A6 and 50F4 hybridized to der(22) while cosmids 2G8 to 148B6 remained to der(12), showing that the breakpoint was located between TEL exons 2 and 3. In FISH experiments, the TEL copy on the unaffected chromosome 12 hybridized with all cosmids, suggesting the absence of gross abnormality. BAC 437G10 encompassing the MN1 gene hybridized to normal 22 and the two derivative chromosomes, suggesting that the MN1 gene was disrupted by the translocation (data not shown).
In the MUTZ-3 cell line, the breakpoint on chromosome 12 has previously been localized within the sequences covered by cosmid 179A6 encompassing the TEL exon 1. TEL exons 3-5 were lost in the copy located to the untranslocated chromosome 12, as shown by FISH experiments with cosmid probes.
2 BAC 437G10 hybridized to der(12) and PAC dJ213J1 gave a split signal on der(12) and der(22), suggesting that the breakpoint was centromeric to MN1 (data not shown). To check for MN1-TEL expression, RT-PCR experiments were carried out using primers corresponding to MN1 exon 1 (MN1-1; gccatgagcaccattga) and TEL exon 4 (TEL-4B; tagaattccagggtggaagaatg). A fragment of the expected size, 382 bp, was amplified from UCSD/AML1 material ( Figure 1a ) and confirmed by nucleotide sequence analyses to correspond to an MN1 exon 1-TEL exon 3 fusion (MN1-TEL type I transcript). In MUTZ-3 cell lines, no MN1-TEL transcript could be amplified as previously described. 2 Expression of normal MN1 transcript was confirmed in both UCSD/AML1 and MUTZ-3 cell lines using MN1-specific primers (MN1-1 and MN1-3; gtcccaaatctgttg gag; Figure 1a) , but was not observed in the controls.
To ensure protein expression, we carried out Western blot analyses with anti-CTEL and anti-MN1 ( 2F2 8 ) antibodies, using standard protocols. In UCSD/AML1 extract, the anti-MN1 antibody reacted strongly with a 200 kDa species, which was not observed in extracts from MUTZ-3 or RPMI8402 (Figure 1b) . The size was consistent with the predicted size of the MN1-TEL protein and with previously published observations. Interestingly, wild-type MN1 proteins (predicted size: 136 kDa) were not observed in these cell extracts. The anti-TEL antibodies reacted with protein species corresponding to the size of normal TEL proteins (50 and 57 kDa) in UCSD/AML1 and RPMI8402 extracts (Figure 1b) . A weak signal was also specifically observed in extracts from UCSD/AML1 that corresponded to the signal observed with anti-MN1 antibody in UCSD/AML1 extracts. This strongly suggests that a bona fide MN1-TEL fusion protein is detected in UCSD/AML1. As expected, no signal corresponding to the MN1-TEL protein was observed in extracts from MUTZ-3 or from RPMI 8402 cells.
Subcellular location of MN1-TEL and TEL proteins was investigated by immunofluorescence experiments with anti-CTEL and anti-MN1 antibodies. Both antibodies generated a spotted fluorescence in the nuclei of cells from UCSD/AML1 (Figure 1d and f, respectively). No signal was observed using MN1 antibodies in the other cell lines tested (data not shown).
Concluding remarks
Hematopoietic malignancies with t(12;22)(p13;q11) are uncommon, and, while only a few cases have been reported until now, various hematopoietic disorders were associated with the abnormality, such as acute myeloblastic leukemia, AML-M4, AML-M2, multilineage acute leukemia, and myelodysplastic syndrome. The MN1-TEL gene fusion, which is associated with the t(12;22), has been reported to encode a transcription factor with transforming activity. To characterize a cellular model suitable for biological studies, we analyzed the myeloid cell line UCSD/AML1, which bears this chromosomal translocation. An MN1-TEL fusion could be detected at the DNA, RNA, and protein levels. Expression of wild-type TEL proteins was observed, but wild-type MN1 proteins could not be detected in those cells. Comparison with the MUTZ-3 cell line shows that different consequences can result from apparently similar chromosome translocations. In MUTZ-3 cells, the t(12;22) translocation is associated with partial deletion of the untranslocated TEL copy, resulting in almost absence of the TEL protein. 2 The reason why the fusion protein is easily detected whereas the wild-type MN1 protein remains under the threshold of detection could be due to various mechanisms, such as stabilization of the RNA or higher transcription levels of the fusion gene due to yet uncharacterized regulatory elements provided by the TEL moiety. Alternatively, stabilization or post-translational modification of the protein could be an important step in the leukemogenesis process, as suggested for the MLL-fusion protein. 9 The leukemic cell line UCSD/AML1, which exhibits MN1-TEL fusion, is a new tool for analyzing the biological consequences of the MN1-TEL fusion. 
